Decrease in leptin production by the adipose tissue in obesity associated with severe metabolic syndrome;Diminuição da produção de leptina pelo tecido adiposo na obesidade associada à síndrome metabólica severa

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 9, 2009, Pages 1088-1095

  da Paz Filho, Gilberto Jorge ^a   Volaco, Alexei ^a   Suplicy, Henrique Lacerda ^a   Radominski, Rosana Bento ^a   Boguszewski, Cesar Luiz ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Adipokines; Leptin; Leptinemia; Metabolic syndrome; Obesity

Indexed keywords

EID: 77149153389     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302009000900005     Document Type: Article

References (52)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: i-xii,1-253.
2. IBGE [Internet]. Pesquisa de Orçamentos Familiares - 2002-2003. Comunicação Social [cited 2009 Mar 10]; Available from: http://www.ibge.gov.br/home/presidencia/noticias/noticia_impres-sao.php? id_noticia=278.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-28.
4. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443(7109):289-95.
5. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S37-50.
6. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-84.
7. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093-103.
8. Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89(10):4821-6.
9. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptindeficient adults. Proc Natl Acad Sci U S A. 2004;101(13):4531-6.
10. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-8.
11. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptinmediated defects. J Clin Endocrinol Metab. 1999;84(10):3686-95.
12. Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, et al. Partial leptin deficiency and human adiposity. Nature. 2001;414(6859):34-5.
13. Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab. 2002;16(4):653-66.
14. Muoio DM, Dohm GL, Fiedorek FT Jr, Tapscott EB, Coleman RA. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes. 1997;46(8):1360-3.
15. Muoio DM, Dohm GL, Tapscott EB, Coleman RA. Leptin opposes insulin's effects on fatty acid partitioning in muscles isolated from obese ob/ob mice. Am J Physiol. 1999;276(5 Pt 1):E913-21.
16. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47-60.
17. Eriksson M, Johnson O, Boman K, Hallmans G, Hellsten G, Nilsson TK, et al. Improved fibrinolytic activity during exercise may be an effect of the adipocyte-derived hormones leptin and adiponectin. Thromb Res. 2008;122(5):701-8.
18. Paz-Filho GJ, Andrews D, Esposito K, Erol HK, Delibasi T, Wong ML, et al. Effects of leptin replacement on risk factors for cardiovascular disease in genetically leptin-deficient subjects. Horm Metab Res. 2009;41(2):164-7.
19. van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25(12):1759-66.
20. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia. 2007;50(6):1178-85.
21. Lawlor DA, Smith GD, Kelly A, Sattar N, Ebrahim S. Leptin and coronary heart disease risk: prospective case control study of British women. Obesity (Silver Spring). 2007;15(7):1694-701.
22. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003;26(10):2883-9.
23. Söderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246(4):409-18.
24. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052-6.
25. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80.
26. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997;10(10 Pt 1):1171-4.
27. Uckaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, et al. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res. 1999;31(7):435-8.
28. McNeely MJ, Boyko EJ, Weigle DS, Shofer JB, Chessler SD, Leonnetti DL, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999;22(1):65-70.
29. Valle M, Gascon F, Martos R, Bermudo F, Ceballos P, Suanes A. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. Int J Obes Relat Metab Disord. 2003;27(1):13-8.
30. Seck T, Englaro P, Blum WF, Scheidt-Nave C, Rascher W, Ziegler R, et al. Leptin concentrations in serum from a randomly recruited sample of 50- to 80-year-old men and women: positive association with plasma insulin-like growth factors (IGFs) and IGF-binding protein-3 in lean, but not in obese, individuals. Eur J Endocrinol. 1998;138(1):70-5.
31. Wang G, Tang J, Chen M. [Association of serum leptin concentrations with blood pressure]. Zhonghua Yi Xue Za Zhi. 1999;79(9):664-7.
32. Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahren B. Reduced leptin concentrations in subjects with type 2 diabetes mellitus in Sudan. Metabolism. 2002;51(3):304-6.
33. Haluzik M, Fiedler J, Nedvidkova J, Ceska R. Serum leptin levels in patients with hyperlipidemias. Nutrition. 2000;16(6):429-33.
34. Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML, et al. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord. 1999;23(10):1066-73.
35. Marinari GM, Scopinaro N, Adami GF. Leptin and HDL-cholesterol in non-diabetic normotensive subjects. Obes Surg. 2001;11(3):252-3.
36. Marita AR, Sarkar JA, Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol Cell Biochem. 2005;275(1-2):143-51.
37. Sayeed MA, Azad Khan AK, Mahtab H, Ahsan KA, Banu A, Khanam PA, et al. Leptin is reduced in lean subjects with type 2 diabetes in bangladesh. Diabetes. Care. 2003;26(2):547.
38. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006;49(9):2086-96.
39. Hu FB, Chen C, Wang B, Stampfer MJ, Xu X. Leptin concentrations in relation to overall adiposity, fat distribution, and blood pressure in a rural Chinese population. Int J Obes Relat Metab Disord. 2001;25(1):121-5.
40. Rodrigues AM, Radominski RB, Suplicy Hde L, De Almeida SM, Niclewicz PA, Boguszewski CL. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab. 2002;87(4):1621-6.
41. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292-5.
42. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab. 1996;81(12):4406-13.
43. Ostlund RE Jr, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab. 1996;81(11):3909-13.
44. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317(5843):1355.
45. Begriche K, Letteron P, Abbey-Toby A, Vadrot N, Robin MA, Bado A, et al. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab. 2008;294(5):E939-51.
46. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006;186(1):5-16.
47. Paz-Filho GJ, Ayala A, Esposito K, Erol HK, Delibasi T, Hurwitz BE, et al. Effects of leptin on lipid metabolism. Horm Metab Res. 2008;40(8):572-4.
48. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171-6.
49. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144(12):5159-65.
50. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003;14(9):398-403.
51. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348(9021):159-61.
52. Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev. 2006;27(7):779-93.